Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

As a result of the stop work order, Vaxart said it had been forced to lay off 10% of its workforce. The company entered the ...

BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...

As the U.S. cuts federal research funding and infrastructure, European countries are strategizing ways to attract top ...

At its annual artificial intelligence-focused GTC conference in San Jose, Nvidia outlined several collaborations with medtech ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

Elevation Oncology is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the ...

After serving as the director of the National Human Genome Research Institute (NHGRI) for more than 15 years, Eric Green, M.D ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...